Lv6
2505 积分 2021-05-19 加入
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
3个月前
已完结
Rethinking End Points in Modern Oncology Trials-Beyond the P Value
4个月前
已关闭
Hepatitis B virus reactivation following T-cell engager therapy in multiple myeloma despite negative hepatitis B core antibody serology: implications for screening in patients with hematological malignancies
7个月前
已完结
Tepotinib plus an EGFR tyrosine kinase inhibitor in patients with EGFR-mutant MET-altered NSCLC: A case series
7个月前
已完结
Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment
7个月前
已完结
Tumor Lysis Syndrome Associated with Monoclonal Antibodies in Patients with Multiple Myeloma: A Pharmacovigilance Study Based on the FAERS Database
8个月前
已完结
A real‑world pharmacovigilance study of FDA adverse event reporting system events for daratumumab
8个月前
已完结
Comprehensive Analysis of Bortezomib-Induced Adverse Events Using the Japanese Real-World Database
8个月前
已完结
皖公网安备34019202002308
